HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yeung, H. W.D. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Yeung, H. W.D. Articles by Larson, S. M.

Radioiodine Uptake in Thyroid Remnants During Therapy After Tracer Dosimetry

Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: Henry W.D. Yeung, MD, Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

ABSTRACT

Our objective was to evaluate the effect of a diagnostic tracer dose of ¹³¹I on the uptake of the therapeutic dose of ¹³¹I in the ablation of a thyroid remnant or residual tumor in patients with differentiated thyroid cancer. Methods: Twelve consecutive patients referred for a dosimetric study and subsequent radioiodine treatment of focal neck uptake of ¹³¹I were studied. The 24-h (in 1 case, 48-h) neck activity was calculated by the region-of-interest method, after both dosimetric and therapeutic administrations. The focal activity in the neck was corrected for decay and compared with the total activity administered to obtain the percentage uptake at 24 h. This procedure was performed for both the scanning dose (range, 19.8–196.1 MBq; mean, 85.1 MBq; median, 40 MBq) and the therapeutic dose (range, 1.073–5.713 GBq; mean, 2.991 GBq). The uptake of the therapeutic dose was then expressed as a percentage of the uptake of the diagnostic dose (%T/D). Counting rate linearity was established up to 350 MBq in the field of view of the camera used in the study. Results: Thirteen of a total of 16 lesions exhibited reduced uptake from the therapeutic dose, 2 remained the same, and in 1 the uptake actually increased from 0.26% to 1.01%. The %T/D ranged from 7.0% to 388.5%, with a mean of 71%. If the lesion with increased uptake is excluded, the range becomes 7.0%-102.1%, with a mean of 50%. Linear regression between the percentage uptake of the diagnostic dose to that of the therapeutic dose results in a slope of 0.42, with a correlation coefficient of only 0.75. We were unable to accurately calculate the radiation dose to the lesion from the diagnostic activity of ¹³¹I, because of uncertainty about the tumor mass. Conclusion: The percentage uptake of the therapeutic dose is on average only one half of that predicted from the dosimetric uptake in thyroid remnants after surgery, even though the median dosimetric dose was only 40 MBq. This reduced uptake should be accounted for in the therapeutic prescription for thyroid ablation or treatment of residual thyroid cancer. We postulate that this effect is caused by radiation damage from the tracer dose during dosimetry.

Key Words: thyroid cancer • radioiodine therapy • stunning

This article has been cited by other articles:

				J. C. Sisson, A. M. Avram, S. A. Lawson, P. G. Gauger, and G. M. Doherty The So-Called Stunning of Thyroid Tissue J. Nucl. Med., September 1, 2006; 47(9): 1406 - 1412. [Abstract] [Full Text] [PDF]

				A F Leger, M Pellan, F Dagousset, A Chevalier, I Keller, and J Clerc A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments Br. J. Radiol., May 1, 2005; 78(929): 428 - 432. [Abstract] [Full Text] [PDF]

				M. Lassmann, M. Luster, H. Hanscheid, and C. Reiners Impact of 131I Diagnostic Activities on the Biokinetics of Thyroid Remnants J. Nucl. Med., April 1, 2004; 45(4): 619 - 625. [Abstract] [Full Text] [PDF]

				J. C. Sisson, B. L. Shulkin, and S. Lawson Increasing Efficacy and Safety of Treatments of Patients with Well-Differentiated Thyroid Carcinoma by Measuring Body Retentions of 131I J. Nucl. Med., June 1, 2003; 44(6): 898 - 903. [Abstract] [Full Text] [PDF]

				P. Postgard, J. Himmelman, U. Lindencrona, N. Bhogal, D. Wiberg, G. Berg, S. Jansson, E. Nystrom, E. Forssell-Aronsson, and M. Nilsson Stunning of Iodide Transport by 131I Irradiation in Cultured Thyroid Epithelial Cells J. Nucl. Med., June 1, 2002; 43(6): 828 - 834. [Abstract] [Full Text] [PDF]

				W. Brenner Is Thyroid Stunning a Real Phenomenon or Just Fiction? J. Nucl. Med., June 1, 2002; 43(6): 835 - 836. [Full Text] [PDF]

				M. Medvedec, J. Hermanska, and L. Jirsa Improved Planning of Radioiodine Therapy for Thyroid Cancer J. Nucl. Med., May 1, 2002; 43(5): 714 - 714. [Full Text] [PDF]

				L. F. Morris, A. D. Waxman, and G. D. Braunstein The Nonimpact of Thyroid Stunning: Remnant Ablation Rates in 131I-Scanned and Nonscanned Individuals J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3507 - 3511. [Abstract] [Full Text] [PDF]

				J. Hermanska, M. Karny, J. Zimak, L. Jirsa, M. Samal, and P. Vlcek Improved Prediction of Therapeutic Absorbed Doses of Radioiodine in the Treatment of Thyroid Carcinoma J. Nucl. Med., July 1, 2001; 42(7): 1084 - 1090. [Abstract] [Full Text] [PDF]

				M. Diehl, F. Grunwald, and H. W.D. Yeung Stunning After Tracer Dosimetry J. Nucl. Med., July 1, 2001; 42(7): 1129 - 1129. [Full Text] [PDF]

				M. Medvedec, H. W.D. Yeung, J. L. Humm, S. M. Larson, V. U. Chengazi, and R. E. O'Mara Thyroid Stunning J. Nucl. Med., July 1, 2001; 42(7): 1129 - 1131. [Full Text] [PDF]